Zachary Zubulake

Transitioning to fully automated assembly lines

The global shift toward self-administration of biologics has driven the exponential demand for pen injectors.

 For pharmaceutical manufacturers and CDMOs, scaling up production to meet this demand requires robust automated assembly lines. While individual machines may boast high theoretical throughput, the overall equipment effectiveness (OEE) often suffers due to micro-stoppages, component variations, and integration complexities between pre-assembly and final assembly stages.

Addressing these bottlenecks requires a holistic systems-engineering approach, focusing on the seamless integration of pre-filled syringe (PFS) handling, dosing mechanism assembly, and rigorous quality control at high speeds.

Challenge 1: Component Variability and High-Speed Feeding

One of the primary causes of micro-stoppages in high-speed assembly lines, operating at 100-160 parts per million (PPM), is the dimensional variability of molded plastic components.

 Even minor deviations within acceptable tolerances can lead to jamming in vibratory bowl feeders or misalignment during robotic pick-and-place operations.

 To mitigate this, advanced assembly lines must employ adaptive feeding systems. Utilizing vision-guided robotics for component orientation rather than relying solely on mechanical sorting significantly reduces jam rates. Furthermore, implementing continuous-motion assembly architectures, in which components are assembled on a moving turret rather than intermittent indexing systems, provides smoother handling of fragile parts and accommodates slight dimensional variations without halting production.

Challenge 2: Precision Alignment in Final Assembly

The final assembly of a pen injector, in which the drug cartridge or pre-filled syringe is integrated with the dosing mechanism, is the most critical phase. The alignment must be perfect to ensure the dose accuracy and the mechanical integrity of the device. Misalignment not only damages the glass cartridge, leading to costly product loss, but also poses severe safety risks to the end-user.

 Achieving precision at 160 PPM requires moving beyond standard pneumatic actuators. Servo-driven pressing stations equipped with force-displacement monitoring provide the necessary control.

 By continuously monitoring the force profile during the pressing operation, the system can detect anomalies, such as a slightly oversized cartridge or a misaligned thread, in milliseconds. If the force profile deviates from the validated parameters, the system can abort the operation before glass breakage occurs, rejecting the specific unit without stopping the entire line.

Challenge 3: Seamless Integration of Pre-Assembly and Final Assembly

Many manufacturers procure pre-assembly equipment and final assembly equipment from different vendors. This fragmented approach often leads to integration bottlenecks in which the transfer of sub-assemblies between machines creates buffer accumulation issues and increases the risk of contamination or damage.

 A turnkey approach, in which a single system supplier provides both the pre-assembly and final assembly lines, eliminates these integration hurdles. This allows for a unified control architecture (e.g., a single PLC/HMI platform) and seamless physical transfer systems. By designing the line as a cohesive unit, manufacturers can implement intelligent buffering systems that dynamically adjust the speed of upstream processes based on downstream demand, maintaining a continuous flow and maximizing overall equipment effectiveness.

Challenge 4: Ensuring Compliance and Accelerating Validation

In the highly regulated pharmaceutical industry, high-speed production is meaningless without stringent quality assurance and comprehensive validation (installation qualification/operational qualification/performance qualification).

Implementing 100% in-line inspection at 160 PPM generates massive amounts of data, which can overwhelm standard control systems.

 Modern assembly lines must integrate edge computing to process vision inspection data locally, ensuring real-time pass/fail decisions without latency.

Furthermore, adopting a quality by design approach during the engineering phase ensures that critical process parameters are continuously monitored and controlled.

 Partnering with equipment suppliers who offer comprehensive validation documentation and regulatory support significantly accelerates the factory acceptance testing/site acceptance testing processes and overall time-to-market.

Scaling up pen injector production to meet global demand requires overcoming significant engineering bottlenecks in component handling, precision assembly, and system integration. By adopting advanced servo-control, vision-guided feeding, and a unified turnkey approach to pre-assembly and final assembly, manufacturers can achieve stable, high-speed production. Partnering with an experienced system supplier who understands both the mechanical intricacies and the stringent regulatory requirements is essential for ensuring product quality and accelerating time-to-market in this competitive landscape.

1. Anselmo, A. C., & Mitragotri, S. (2014). An overview of clinical and commercial impact of drug delivery systems. 

https://doi.org/10.1016/j.jconrel.2014.03.053

2. Perrone, M. G., & Maiocchi, M. (2022). 

Applying lean methodologies to improve the OEE of a manufacturing line: a case study in a pharmaceutical company

https://www.politesi.polimi.it/handle/10589/204180

3. Srai, value, S. C., Badman, C., … & Florence, A. J. (2015). Future supply chains enabled by continuous processing—opportunities and challenges. 

Efficient force-displacement monitoring and process control for medical device assembly

5.International Society for Pharmaceutical Engineering (ISPE). (2008). 

GAMP 5: A Risk-Based Approach to Compliant GxP Computerized Systems

6. Sharma, D., et al. (2023). A comprehensive study on Industry 4.0 in the pharmaceutical sector. 

https://doi.org/10.1007/s10668-023-03225-8

7. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). (2009). 

ICH Harmonised Tripartite Guideline: Pharmaceutical Development Q8(R2)

https://database.ich.org/sites/default/files/Q8_R2_Guideline.pdf

Articles

Surging global adoption of self-administered biologics is forcing rapid scale-up of pen-injector manufacturing, where realized throughput is constrained by OEE losses from micro-stoppages, part variability, and handoffs between pre- and final-assembly modules. Key failure modes include molded-component dimensional drift that disrupts high-speed feeding, tight alignment tolerances during PFS/cartridge integration, and vendor-fragmented line architectures that create buffering and contamination risks. Mitigations center on vision-guided adaptive feeding, continuous-motion platforms, servo pressing with force–displacement analytics, turnkey integrated controls, and edge-computing-enabled inline inspection aligned with QbD and GxP validation.

GLP-1 / insulin demand is straining CDMO fill-finish capacity. This piece examines bottlenecks in automated pen injector assembly and strategies to optimize operations.

Overcoming Fill-Finish Capacity Bottlenecks in Automated Pen Injector Assembly Lines

Molly Klote, President and CEO, Klote Medical Research Advisors

 spoke with Dr. Molly Klote, president and CEO, Klote Medical Research Advisors, and moderator of the conference's regulatory track panel, about what the industry must do to navigate a rapidly changing supply chain landscape.

Molly Klote on Reshoring, Tariffs, and the Future of Pharma Supply Chains

PharmTech: What Is Driving the Current Push To Rethink Pharmaceutical Supply Chains?

 The pressure extends well beyond tariffs, though tariffs are clearly part of it. Companies are also responding to geopolitical instability, supplier concentration risks, inspection vulnerabilities, shortage exposure, and deep uncertainty around future policy direction. What I'm hearing from people here at the meeting is that the unpredictability may be as disruptive as the cost itself. Companies need to make long-range manufacturing, sourcing, and regulatory decisions, and they're doing so without knowing which countries will reliably serve as sources or what trade conditions will look like 12 to 24 months from now. That volatility is the core challenge.

For years, the default approach was to source from wherever costs were lowest. That model is no longer sustainable on its own. Companies are now asking how they can build in resilience through dual sourcing, qualified backup suppliers, or greater transparency into their tier-two and tier-three suppliers without restructuring their cost base so dramatically that it compromises affordability or patient access.

Is the Industry Actually Moving Manufacturing Back to the United States?

Not wholesale, and I think it's important to be clear about that. Some selective onshoring is happening, and it makes sense in certain contexts. But the more realistic trend is regionalization combined with supply chain redundancy, building in alternatives rather than relocating everything domestically. Not everything can or should be reshored here. The real work is determining which parts of the supply chain are critical enough to justify higher cost or redundancy and then making those changes in a way that doesn't undermine the affordability and availability of medicines for patients. That balance is difficult, and it requires careful, strategic thinking rather than a reactive response to political pressure.

What Will FDA Be Looking for From Companies as They Adapt Their Supply Chain Strategies?

The FDA is not looking for slogans about resilience. Companies need to be prepared to demonstrate through evidence how they are making resilience a reality. That means having current supply chain maps, formal risk assessments, credible alternate-source strategies, realistic regulatory pathways for supplier or site changes, and governance mechanisms that define when and how the organization responds as risks escalate.

A credible resilience strategy must also be quality-led, not simply procurement-driven. For the FDA, the central question will be whether a company understands its vulnerabilities and has a controlled, documented, and regulatorily realistic plan to protect patients if a supplier, site, country, or logistics route becomes unavailable.

What Regulatory Shifts Should Professionals Expect?

Three things stand out. First, there will be more data-driven FDA oversight of supply chains. The agency wants to see what companies are doing more than what they intend to do. Second, companies should anticipate more risk-based and globally consistent inspection oversight for anything that is globally outsourced. Third, there will be stronger expectations around formal quality risk management. Quality must be built in from the start. The FDA's focus is patient safety, and if your systems are not oriented around that, that is where you will run into serious problems.

What Is Your Overall Message to Companies Navigating This Environment?

Act now and act with specificity. The uncertainty in the current environment is not going away, and the companies that will be best positioned, both commercially and regulatorily, are the ones that treat supply chain resilience as a quality and patient safety imperative, not an external compliance requirement. FDA will reward the companies that can demonstrate they understand their risks and have taken documented, defensible steps to address them.

Escalating tariffs intersect with geopolitical instability, supplier concentration, inspection vulnerabilities, and drug-shortage exposure to force a rethink of pharma supply chains. Unpredictable policy trajectories are as disruptive as direct cost impacts, complicating 12–24 month manufacturing and sourcing commitments. Rather than broad US reshoring, the dominant response is regionalization plus redundancy, emphasizing dual sourcing and deeper tier-2/3 visibility while preserving affordability and access. FDA expectations are shifting toward evidence-based demonstrations of resilience, quality-led governance, formal risk management, and regulatorily executable pathways for supplier and site changes.

Molly Klote, Klote Medical Research Advisors, discusses how pharma must move beyond tariff-driven reactions to build evidence-based, quality-led supply chain resilience that satisfies FDA scrutiny and protects patient access.

Q&A: Molly Klote on Dual Sourcing, Regionalization, and the New Pharma Normal

GSK Acquires Nuvalent to acquire their highly selective inhibitors targeting ROS1 and ALK gene alterations

GSK has entered into an agreement to acquire Nuvalent, a Boston-based clinical-stage biopharmaceutical company, for $10.6 billion, marking one of the more significant oncology deals of 2026.

 The transaction centers on two late-stage kinase inhibitors, zidesamtinib and neladalkib, both are currently under FDA review with potential approval decisions later in 2026. The deal reflects a broader trend in pharmaceutical dealmaking: acquiring programs with clinically validated targets that address measurable gaps in efficacy or tolerability relative to existing standard-of-care therapies.

What Makes These Compounds Distinct from Existing Therapies?

Zidesamtinib and neladalkib are highly selective inhibitors targeting ROS1 and ALK gene alterations, respectively, in non-small cell lung cancer.

 Both have received FDA Breakthrough Therapy and Orphan Drug designations. Their clinical profiles are built around high target selectivity, durable response rates, improved tolerability compared to earlier-generation inhibitors, enhanced blood-brain barrier penetration, and broader mutation coverage.

Non-small cell lung cancer with ROS1 or ALK alterations primarily affects non-smoking adults between 40 and 50 years old.

 Current therapies in this space are associated with resistance mutations and side effects including metabolic and neurologic events that limit long-term use. The new compounds aim to extend effective treatment duration while reducing the adverse event burden.

Data for both assets were presented at major oncology conferences in 2025 and 2026, lending the programs a degree of clinical credibility ahead of their anticipated regulatory decisions.

 Target action dates are set for September 18 for zidesamtinib and November 27 for neladalkib.

How Will This Reshape GSK's Development and Commercial Infrastructure?

From a pipeline architecture standpoint, GSK is positioning this acquisition as a platform play in lung cancer rather than a single-asset transaction. The deal also includes NVL-330, a HER2 inhibitor in phase I trials for HER2-altered non-small cell lung cancer.

 GSK intends to build on this foundation using its own B7-H3 antibody-drug conjugate, currently in phase III development, creating a multi-asset lung cancer franchise.

Both lead assets are small molecules developed using structure-based drug design, a modality that generally offers more established manufacturing pathways than biologics or cell-based therapies.

 Should the FDA approvals come through in 2026 as anticipated, rapid commercial-scale production planning will need to be underway well in advance.

Under the agreement terms, GSK will offer $124 per share in cash, a 40% premium to Nuvalent's last closing price.

The transaction is funded through a combination of new and existing debt facilities and cash and is expected to close in the third quarter of 2026, pending regulatory clearance and shareholder tender conditions.

How Does the GSK-Nuvalent Deal Fit into the Broader Oncology Dealmaking Landscape?

The GSK-Nuvalent acquisition is one of several major oncology transactions announced in recent weeks, reflecting sustained industry confidence in targeted therapies with clinically validated mechanisms.

Johnson & Johnson separately agreed to acquire Firefly Bio for $1 billion

, targeting its degrader antibody conjugate platform designed to reach KRAS-driven tumors.

Roche, meanwhile, entered a licensing and collaboration agreement with Nurix Therapeutics valued at up to $3 billion

 to co-develop a BTK degrader for blood cancers.

 These deals suggest that large pharmaceutical companies are prioritizing platform acquisitions and multi-program collaborations over single-asset transactions as the dominant model for pipeline expansion.

GSK. GSK enters agreement to acquire Nuvalent, Inc. Press Release. June 9, 2026. 

https://www.gsk.com/en-gb/media/press-releases/gsk-enters-agreement-to-acquire-nuvalent-inc

Johnson & Johnson. Johnson & Johnson to acquire Firefly Bio, Inc. to expand oncology pipeline with novel degrader antibody conjugate platform. Press Release. June 8, 2026. 

https://www.jnj.com/media-center/press-releases/johnson-johnson-to-acquire-firefly-bio-inc-to-expand-oncology-pipeline-with-novel-degrader-antibody-conjugate-platform

Roche. Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology. Press Release. June 8, 2026. 

https://www.roche.com/media/releases/med-cor-2026-06-08

GSK will acquire Nuvalent for $10.6B to secure late-stage, highly selective ROS1 and ALK inhibitors in NSCLC, with FDA action dates anticipated in September (zidesamtinib) and November 2026 (neladalkib). Both programs emphasize durability, CNS penetration, tolerability, and mutation coverage versus earlier-generation TKIs in younger, often never-smoking populations. The transaction also adds an early HER2 program (NVL-330) and supports a broader lung cancer franchise strategy alongside GSK’s phase III B7-H3 ADC. Deal financing is debt-plus-cash, at a 40% premium.

GSK boosts oncology pipeline with Nuvalent acquisition, advancing FDA-designated ROS1/ALK inhibitors for NSCLC and expanding kinase inhibitor drug development in lung cancer.

GSK Acquires Nuvalent for $10.6 Billion in Lung Cancer Push

CPHI Americas Panel Making the Case for Product Carbon Footprints

Requests for carbon emissions data from customers or procurement teams may have once seemed peripheral to the core business. That is changing rapidly. During a presentation attended by 

, sustainability consultant David Vázquez, climate principal consultant, Nexius Projects, laid out a clear picture of why product carbon footprints (PCFs), the emissions associated with a product across its entire lifecycle, are moving from voluntary best practice to a baseline commercial and regulatory expectation.

The distinction between corporate-level emissions reporting and product-level carbon accounting matters significantly for suppliers in the pharmaceutical value chain, noted Vázquez. Corporate reporting captures the emissions associated with running operations, energy use, fleets, and facilities. A product carbon footprint, by contrast, traces emissions from raw material extraction through to end-of-life waste management. For a packaging supplier to a pharmaceutical manufacturer, for example, that means accounting for every stage from the sourcing of raw materials through to how the packaging is ultimately disposed of. As Vázquez put it during the presentation, “A product carbon footprint helps us to understand the impacts on climate of that specific product and understand exactly at which stage of the value chain the impact is higher, so that we can use them to make decisions."

When a pharmaceutical company has committed to science-based emissions targets or must comply with frameworks such as the European Corporate Sustainability Reporting Directive or California's climate disclosure regulation, the data gaps almost always sit in what is classified as Scope 3, indirect emissions generated across the value chain, including purchased goods and services. 

AstraZeneca's release of a supplier guide in April requiring carbon data from its supply base is one visible example of how this expectation is being operationalized, according to Vázquez. The National Health Service in the UK has similarly introduced supplier emissions reporting requirements, and France is set to implement regulation mandating that companies supplying medicines to hospitals provide detailed, high-quality product carbon footprints. "This is not something that is done just to tick a box," Vázquez noted. "It is something that is currently growing and has large focus from regulators and also from other stakeholders."

Vázquez made the argument that a PCF was not about regulatory obligation, but about operational value. PCFs, when calculated rigorously, function as a diagnostic tool for manufacturing processes. Emissions intensity often tracks closely with process inefficiencies like energy-heavy steps, suboptimal raw material choices, or process routes that have not been scrutinized through a resource lens. Understanding where emissions are concentrated in a production process can surface opportunities to reduce costs and improve yields that might not have been visible through conventional operational review alone. "Something that is sometimes forgotten when we talk about sustainability is that it is not only about climate," Vázquez said. "It is also about being more efficient and reducing costs. That is why product carbon footprints have huge potential; they also uncover inefficiencies that maybe we are not aware of."

This reframing is practically important for professionals tasked with making the internal case for investing in data collection. Approaching operations leadership with a proposal framed around climate action is a harder sell in the current environment than presenting the same exercise as a tool for identifying production inefficiencies, maintaining customer relationships, and keeping pace with regulatory requirements across global markets.

The methodology for calculating PCFs is well-established. Standards including ISO 14067 and the Greenhouse Gas Protocol provide step-by-step guidance, and software tooling has matured considerably. Vázquez’s advice for organizations starting out was to resist the pressure to do everything at once, selecting a single product, defining the appropriate system boundary based on what a specific customer or regulator is asking for, and building from there is a workable approach. Vázquez framed the broader shift as "understanding your product emissions is the next stage in your climate journey. The first stage was understanding your corporate emissions, but now you need to put more emphasis on these things."

The window in which this can be treated as a niche sustainability concern is closing. The organizations building data collection and carbon accounting capabilities now are likely to find themselves better positioned, commercially and operationally, as requirements from both customers and regulators continue to tighten.

Product carbon footprints are rapidly becoming an expected commercial deliverable across the pharma value chain, driven by Scope 3 disclosure mandates and customer procurement requirements. Unlike corporate emissions inventories, PCFs quantify cradle-to-grave impacts and pinpoint value-chain stages driving the largest climate burden. Rigorous PCFs can also function as operational diagnostics, surfacing energy- and material-intense steps that correlate with inefficiency, cost, and yield loss. Mature standards and tools enable phased adoption by piloting one product and fit-for-purpose system boundaries.

Pharmaceutical suppliers face growing pressure to calculate product carbon footprints as customer requirements and global regulations tighten.

CPHI Americas: The Business Case for Product Carbon Footprints in Pharma

A comprehensive comparative evaluation of three primary clinical data management architectures

As healthcare organizations transition toward data-driven paradigms, the volume and variety of datasets, ranging from electronic health records (EHRs) and genomic sequencing to wearable sensor streams and high-resolution radiology images, have grown exponentially.

 The global volume of healthcare data was estimated to reach 2,314 exabytes by 2020, and this trajectory has only accelerated with the adoption of Internet of Things (IoT) devices and remote patient monitoring platforms.

 The successful deployment of AI applications in clinical settings hinges critically on the underlying data management architecture. AI models require high-quality, bias-controlled, and representative training data to avoid the well-known “garbage in, garbage out” phenomenon. Furthermore, transparency through provenance tracking and versioning, standards-based interoperability for seamless data exchange, and the ability to handle large, multimodal datasets are non-negotiable prerequisites for any organization serious about clinical AI.

To evaluate the efficacy of data management solutions in this demanding context, industry standards increasingly rely on two complementary frameworks. The FAIR principles ensure that data is findable through unique persistent identifiers, accessible via standard communication protocols, interoperable through machine-readable formats and standardized vocabularies such as SNOMED-CT and LOINC, and reusable with clear licensing and domain-specific metadata.

 The 5 V’s of Big Data address the technical challenges of managing large-scale clinical datasets: 

Volume (the sheer size of EHR, genomic, and imaging data) 

Variety (the heterogeneity of structured, semi-structured, and unstructured formats) 

Velocity (the need for both batch and real-time processing)

Veracity (data quality, integrity, and traceability)

Value (the ability to extract actionable insights for research and patient care). 

Adopting this combined FAIR-5V perspective enables healthcare institutions to build future-proof infrastructures that support both clinical operations and AI research.

The Three Pillars of Clinical Data Architecture

Clinical Data Warehouses: The Bastion of Governance

The Clinical Data Warehouse (cDWH) has been the established standard in healthcare data management for decades. Designed as a central data hub, it harmonizes data from various clinical sources, enforces interoperability standards, and organizes patient data into highly structured, tabular formats using a “schema-on-write” approach. A defining characteristic of cDWHs is their adherence to atomicity, consistency, isolation, and durability (ACID) properties, which ensures that every transaction is dependable, and data integrity is maintained even in the event of system failures. Atomicity guarantees all-or-nothing execution, consistency ensures data remains valid before and after transactions, isolation prevents concurrent transactions from interfering with each other, and durability ensures committed data persists permanently.

These properties make cDWHs exceptionally well-suited for environments requiring strict regulatory compliance, reliable structured analysis, and straightforward auditing.

 They provide a stable foundation for training robust machine learning models on clean, well-cataloged tabular data, and are particularly valuable for hospital governance, long-term trend analyses, and business intelligence dashboards. However, cDWHs face significant challenges in the modern AI landscape. The rapid influx of unstructured data, such as radiology images, clinical notes, and waveform recordings, makes it increasingly difficult to maintain the rigid, fixed schema approach. Every new data element requires ETL (Extract, Transform, Load) reengineering, and scaling up to accommodate images, notes, or real-time feeds is both costly and slow. Furthermore, the batch-oriented processing model of cDWHs can delay the detection of acute clinical events, limiting their utility for time-critical medical decision-making.

Clinical Data Lakes (cDL): Flexibility and Scale

To address the limitations of cDWHs, the Clinical Data Lake (cDL) emerged as an architectural approach that enables the storage of vast amounts of raw data in its original format, whether structured EHR records, semi-structured HL7 or FHIR messages, or unstructured radiology images and clinical notes. Unlike cDWHs, cDLs utilize a “schema-on-read” approach, allowing organizations to ingest and store data without defining a schema upfront.

 This provides exceptional scalability and flexibility, enabling multimodal patient views and supporting near real-time data processing through distributed file systems and big data frameworks such as Hadoop and Spark.

cDLs are highly cost-effective for storing petabytes of diverse data and are well-suited for exploratory research, machine learning prototyping, IoT and streaming data analysis, and future-proofing data assets for emerging analytic methods. However, this flexibility comes at a significant governance cost. Without disciplined metadata management and robust data governance policies, a cDL can quickly degrade into a “data swamp,” a repository where data becomes unfindable, unreliable, and ultimately unusable. The absence of built-in enforcement for data types or business rules means that imputation logic and provenance tracking must be manually recoded for every study, posing challenges for maintaining data quality and veracity across large-scale research programs.

Clinical Data Lakehouses (cDLH): The Hybrid Frontier

The Clinical Data Lakehouse (cDLH) represents a newer, more complex hybrid approach that seeks to combine the scalable storage capabilities of a cDL with the structured queries, performance optimizations, and ACID transaction guarantees of a cDWH. First conceptualized by Zaharia et al. (2021), the lakehouse architecture applies open data formats and comprehensive data management techniques to provide a unified platform where raw data can be stored cost-effectively and processed in structured formats as required. In the clinical context, cDLHs combine a lake-style raw data landing zone with warehouse-style Delta or ACID tables and a single metastore that tracks both processed and unprocessed assets.

cDLHs offer the most comprehensive capabilities among the three architectures, supporting both real-time data ingestion and structured querying within a single platform. They are ideal for large, research-intensive institutions that need to integrate classic tabular data with vast amounts of unstructured research data such as images and omics data, enabling both standard reporting and advanced AI applications on the same dataset. However, cDLHs are extraordinarily complex, often cloud-native, and require interdisciplinary expertise spanning traditional data warehousing principles, modern big data methods (distributed systems, streaming), and DevOps practices including Docker, Kubernetes, and identity management. The initial setup and ongoing maintenance demand significant resources, posing a particular challenge for organizations with limited technical capacity.

Comparative Evaluation Across the 5 Vs of Big Data

To systematically assess these architectures, this article evaluates them against the 5 V’s of Big Data using an illustrative scoring framework derived from the qualitative findings of Gebler et al. (2025).

 As shown in the radar chart below, cDWHs score highly on Veracity, reflecting their strict schema enforcement and ACID compliance, but lag significantly in Variety (limited to structured formats) and Velocity (batch-oriented processing). Conversely, cDLs excel in Volume and Variety due to their schema-on-read flexibility and distributed storage, but struggle with Veracity owing to weaker governance controls. The cDLH architecture achieves consistently high scores across all five dimensions, reflecting its hybrid design that balances governance with flexibility, though at the cost of greater implementation complexity.

Navigating Complexity: Implementation, Maintenance, and Expertise

Beyond technical performance across the 5 V’s, healthcare executives and technical leaders must carefully weigh the operational trade-offs associated with each architecture. Gebler et al. identify four critical dimensions of complexity: implementation effort, maintenance and scalability, required technical expertise, and coordination complexity.

: cDWHs require detailed data models, extensive ETL development, and a stable database system, typically following a fixed project plan with defined phases for schema design, ETL development, testing, and go-live. Although the initial effort is high, the resulting structure is clear and stable for consistent data management. cDLs benefit from a schema-on-read approach that reduces upfront modeling, but continuous maintenance and expertise in big data technologies such as Hadoop and cloud object storage are essential. cDLHs demand the orchestration of both schema-on-write and schema-on-read functionalities, complex ETL or transform pipelines, robust security concepts, and distributed compute environments, resulting in the highest initial integration and development effort among the three architectures.

: cDWHs require continuous maintenance for schema extensions, data source changes, and performance tuning, with vertical scaling becoming increasingly expensive as data volumes grow. The batch-oriented structure can become a bottleneck for real-time applications. cDLs offer cost-effective horizontal scaling through distributed file systems but require active monitoring, strict data governance, and continuous quality management to prevent data swamp degradation. cDLHs support dynamic scalability for both compute and storage but involve the most complex maintenance regime, as both the lake and warehouse components must be independently managed and synchronized.

: cDWHs rely on well-established skills in relational databases, SQL, and ETL tools. cDLs demand expertise in big data frameworks (Hadoop, Spark), streaming tools (Kafka, Flume), and cloud storage, along with proficiency in analyzing and modeling unstructured data. cDLHs require the broadest range of interdisciplinary expertise, combining traditional data warehousing knowledge with big modern data techniques and cloud-native DevOps practices, a combination that poses a significant staffing challenge for many healthcare organizations.

Strategic Recommendations and Application Scenarios

The optimal data management architecture depends heavily on an organization’s specific needs, available resources, data landscape, and strategic goals. Drawing on the comparative analysis and real-world implementations documented by Gebler, et al., the following scenario-based recommendations are presented.

It is important to note that cost analysis and legacy system integration also play critical roles in architecture selection. While cDWHs may have high upfront costs due to extensive ETL development and schema design, they often offer lower long-term operational costs due to their stable nature.

 cDLs offer cost-effective scalability for large datasets but require ongoing investment in metadata management and system monitoring. cDLHs promise a balance between structure and flexibility but require significant initial integration costs and ongoing maintenance. Healthcare organizations should also consider their existing IT infrastructure: cDWHs generally offer smoother integration with established relational databases and clinical information systems, while cDLs and cDLHs may require additional transformation layers and custom connectors.

Building Resilient, Future-Proof Data Ecosystems

As the healthcare sector continues to embrace AI and advanced analytics, the underlying clinical data infrastructure must evolve to meet increasingly demanding requirements. Clinical Data Warehouses provide the necessary stability, governance, and auditability for structured reporting and regulatory compliance, but they are increasingly constrained by the volume and variety of modern medical data.

 Clinical Data Lakes offer the requisite scale and flexibility for exploratory research and machine learning innovation, but they introduce significant governance risks that can undermine data quality if not carefully managed. The Clinical Data Lakehouse emerges as the most comprehensive solution, bridging the gap between structured reliability and unstructured flexibility while supporting both real-time and batch analytics on a unified platform.

However, the high technical complexity and implementation costs of cDLHs mean they are currently best suited for large, research-intensive institutions with the resources and expertise to manage hybrid environments.

 Future research and development should focus on reducing the complexity of lakehouse implementations, improving the integration of clinical standards such as HL7 FHIR, and developing more accessible tooling that lowers the barrier to entry for smaller organizations. Ultimately, healthcare organizations must align their architectural choices with their immediate analytical needs, long-term scalability goals, and available technical expertise to build resilient, future-proof data ecosystems that serve both clinical operations and the advancing frontier of AI-driven medical research.

Disclaimer: The views expressed in the article are those of the authors and not of the organizations they represent.

Gebler R, Reinecke I, Sedlmayr M, Goldammer M. 

Enhancing Clinical Data Infrastructure for AI Research: Comparative Evaluation of Data Management Architectures

. J Med Internet Res. 2025;27: e74976. doi:10.2196/74976.

Shilo S, Rossman H, Segal E. Axes of a revolution: challenges and promises of big data in healthcare. 

. 2020;26(1):29-38. doi:10.1038/s41591-019-0727-5.

Baloch L, Bazai SU, Marjan S, Aftab F, Aslam S, Neo T, et al. A review of big data trends and challenges in healthcare. 

. 2023;14(6):1320. doi:10.14716/ijtech. v14i6.6643.

Wilkinson MD, Dumontier M, Aalbersberg IJ, et al. The FAIR Guiding Principles for scientific data management and stewardship. 

. 2016; 3:160018. doi:10.1038/sdata.2016.18.

Pavlenko E, Strech D, Langhof H. Implementation of data access and use procedures in clinical data warehouses: a systematic review of literature and publicly available policies. 

. 2020;20(1):157. doi:10.1186/s12911-020-01177-z.

Sebaa A, Chikh F, Nouicer A, Tari A. Medical big data warehouse: architecture and system design, a case study: improving healthcare resources distribution. 

. 2018;42(4):59. doi:10.1007/s10916-018-0894-9.

El Aissi ME, Benjelloun S, Loukili Y, Lakhrissi Y, El Boushaki AE, Chougrad H, et al. Data lake versus data warehouse architecture: a comparative study. In: 

Proceedings of the 6th International Conference on Wireless Technologies, Embedded, and Intelligent Systems

. 2020. doi:10.1007/978-981-33-6893-4_19.

Quix C, Hai R. Data Lake. In: Sakr S, Zomaya AY, editors. 

Zaharia M, Ghodsi A, Xin R, Armbrust M. Lakehouse: a new generation of open platforms that unify data warehousing and advanced analytics. In: 

Proceedings of the 11th Conference on Innovative Data Systems Research

Harby AA, Zulkernine F. From data warehouse to Lakehouse: a comparative review. In: 

Proceedings of the 2022 IEEE International Conference on Big Data

. 2022. doi:10.1109/BigData55660.2022.10020719.

Nambiar A, Mundra D. An overview of data warehouse and data lake in modern enterprise data management. 

. 2022;6(4):132. doi:10.3390/bdcc6040132.

Bellazzi R. Big data and biomedical informatics: a challenging opportunity. 

. 2014;9(1):8-13. doi:10.15265/IY-2014-0024.

Lee CH, Yoon HJ. Medical big data promises and challenges. 

. 2017;36(1):3-11. doi: 10.23876/j.krcp.2017.36.1.3.

Begoli E, Goethert I, Knight K. A Lakehouse architecture for the management and analysis of heterogeneous data for biomedical research and mega-biobanks. In: 

Proceedings of the 2021 IEEE International Conference on Big Data

. 2021. doi:10.1109/BigData52589.2021.9671534.

Xiao Q, Zheng W, Mao C, Hou W, Lan H, Han D, et al. MHDML: construction of a medical Lakehouse for multi-source heterogeneous data. In: 

Proceedings of the 11th International Conference on Health Information Science

. 2022. doi:10.1007/978-3-031-20627-6_12.

AI-ready clinical data infrastructures must accommodate rapidly expanding multimodal data while preserving quality, provenance, interoperability, and regulatory-grade governance. Using FAIR principles alongside the 5 V’s of Big Data clarifies architectural trade-offs among clinical data warehouses, lakes, and lakehouses. Warehouses deliver ACID-backed veracity and auditability but struggle with unstructured data and real-time needs. Data lakes scale for volume/variety and exploratory AI, yet risk “data swamps” without strong metadata and governance. Lakehouses unify both paradigms, enabling batch and streaming analytics, but impose substantial complexity, cloud-native tooling demands, and resourcing burdens.

Three primary clinical data management architectures--Clinical Data Warehouses, Clinical Data Lakes, and Clinical Data Lakehouses--are the newest technologies aiming to leverage AI for predictive analytics.

Enhancing Clinical Data Infrastructure for AI Research: A Strategic Guide for Pharma Professionals

J&J and Roche Make Big M&A Moves for Protein Degraders

Two major pharmaceutical transactions announced this week underscore a growing industry conviction that targeted protein degradation represents the next frontier in oncology.

 Johnson & Johnson announced that it has entered into a definitive agreement to acquire Firefly Bio, Inc. for $1 billion in cash.

 The deal centers on Firefly's Firelink degrader antibody conjugate platform, which is designed to deliver a highly selective protein degrader directly to tumor cells while sparing healthy tissue. The technology targets KRAS-driven tumors, a historically difficult area in which patients with advanced disease often face survival measured in months. “KRAS has notoriously been considered an undruggable target and patients with KRAS-driven cancers continue to face limited treatment options with survival measured in months, not years,” said John Reed, M.D., Ph.D., Executive Vice President, Innovative Medicine, Research & Development, Johnson & Johnson, in a press release.

 “We believe the proprietary Firelink™ platform will overcome the limitations of current treatments and diversify our pipeline with preclinical candidates for treating multiple types of solid tumors.”

In parallel, Roche announced an exclusive licensing and collaboration agreement with Nurix Therapeutics to co-develop and co-commercialize bexobrutideg, an investigational oral Bruton's Tyrosine Kinase (BTK) degrader.

 Unlike conventional inhibitors that block kinase activity, bexobrutideg is designed to eliminate the target protein entirely, removing both its kinase and scaffolding functions. That distinction is clinically significant, as acquired resistance mutations that undermine existing inhibitor therapies would be less likely to protect a target that no longer exists in the cell. Nurix will receive an upfront payment of $700 million and is eligible for development, regulatory, and sales milestones totaling up to $2.3 billion.

Why Are These Platforms Attracting This Level of Investment?

The combined non-Hodgkin lymphoma and chronic lymphocytic leukemia market is projected to reach $41 billion by 2031, with BTK inhibitors expected to account for roughly $19 billion of that figure.

 Resistance and tolerability issues continue to erode long-term outcomes for patients, this could create an opening for degrader-based approaches that could offer more durable responses.

The Roche-Nurix collaboration is structured as a co-development and co-commercialization arrangement, with development costs split 60-40 in Roche's favor and U.S. profits shared equally.

 Phase III initiation in chronic lymphocytic leukemia is planned for summer 2026, which means manufacturing scale-up timelines are not far off. The J&J-Firefly transaction is expected to close later this year pending regulatory approval.

Are Broad Collaboration Strategies Becoming the New Standard for Oncology Innovation?

In this previous month, the deals have extended beyond platform acquisitions and degrader technology.

 A parallel trend is emerging in oncology drug development: large-scale, multi-program collaboration agreements that pool discovery capabilities across geographies and modalities to accelerate early-stage pipelines.

Bristol Myers Squibb (BMS) and Hengrui Pharma announced a global strategic collaboration spanning 13 early-stage programs across oncology, hematology, and immunology.

 The agreement, valued at up to $15.2 billion in total potential milestones, includes a $600 million upfront payment and structures joint discovery responsibilities around each company's complementary strengths, Hengrui's early-stage development efficiency and discovery engine paired with BMS's global regulatory and commercial infrastructure.

Johnson & Johnson is acquiring Firefly Bio for $1 billion to access an antibody–degrader conjugate platform intended to deliver selective protein degraders to KRAS-driven tumors, aiming to improve therapeutic index in a historically refractory setting. Roche is licensing and co-developing Nurix’s oral BTK degrader bexobrutideg, with $700 million upfront and up to $2.3 billion in milestones, positioning degradation to address inhibitor resistance by eliminating both kinase and scaffolding functions. Concurrently, multi-program, modality-spanning collaborations are accelerating oncology pipeline generation and complicating CMC demands.

J&J and Roche commit billions to protein degrader platforms, signaling a new era in oncology drug development with major manufacturing implications.